Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 2/3 1

Status

Recruiting 3Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Endocrine 6Gastrointestinal 1

Conditions

Neuroendocrine Tumors 35Carcinoid Tumor 8Adenoma, Islet Cell 6Neoplasms 5Neoplasm Metastasis 3Carcinoma, Neuroendocrine 3Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Tuberous Sclerosis 1Thymus Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Metatropic dwarfism 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Glioblastoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1

Interventions

Everolimus 6Sunitinib 3Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Injections 2recombinant interferon alpha 2b-like protein 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1fludarabine phosphate 1cabozantinib 1batifiban 1abemaciclib 1X-Rays 1Sorafenib 1Phantoms, Imaging 1PM 01183 1Oxaliplatin 1Leucovorin 1Interleukin-13 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cryotherapy 1Biopsy 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Everolimus × NET × Clear all
NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
22 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00942682 2014-04-29

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
21 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡